BRPI0610477A2 - composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma infecção bacteriana, de uma inflamação e de fibrose cìstica em um paciente com necessidade do mesmo - Google Patents

composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma infecção bacteriana, de uma inflamação e de fibrose cìstica em um paciente com necessidade do mesmo Download PDF

Info

Publication number
BRPI0610477A2
BRPI0610477A2 BRPI0610477-0A BRPI0610477A BRPI0610477A2 BR PI0610477 A2 BRPI0610477 A2 BR PI0610477A2 BR PI0610477 A BRPI0610477 A BR PI0610477A BR PI0610477 A2 BRPI0610477 A2 BR PI0610477A2
Authority
BR
Brazil
Prior art keywords
substituted
group
formula
unsubstituted
compound
Prior art date
Application number
BRPI0610477-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Guoqiang Wang
Ly Tam Phan
Yat Sun Or
Yao-Ling Qiu
Deqiang Niu
Yulin Peng
Marina Busuyek
Yanchun Wang
Suanne Nakajima
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/122,251 external-priority patent/US20060252710A1/en
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of BRPI0610477A2 publication Critical patent/BRPI0610477A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0610477-0A 2005-05-04 2006-05-02 composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma infecção bacteriana, de uma inflamação e de fibrose cìstica em um paciente com necessidade do mesmo BRPI0610477A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67767505P 2005-05-04 2005-05-04
US60/677,675 2005-05-04
US11/122,251 US20060252710A1 (en) 2005-05-04 2005-05-04 6-11 Bridged oxime erythromycin derivatives
US11/122,251 2005-05-04
PCT/US2006/016882 WO2006119313A2 (en) 2005-05-04 2006-05-02 6-11 bridged oxime erythromycin derivatives

Publications (1)

Publication Number Publication Date
BRPI0610477A2 true BRPI0610477A2 (pt) 2010-06-22

Family

ID=37308644

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610477-0A BRPI0610477A2 (pt) 2005-05-04 2006-05-02 composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma infecção bacteriana, de uma inflamação e de fibrose cìstica em um paciente com necessidade do mesmo

Country Status (8)

Country Link
EP (1) EP1885737A4 (es)
JP (1) JP2008540432A (es)
AU (1) AU2006242188A1 (es)
BR (1) BRPI0610477A2 (es)
CA (1) CA2605295A1 (es)
MX (1) MX2007013730A (es)
TW (1) TW200716143A (es)
WO (1) WO2006119313A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201076A2 (en) * 2017-04-28 2018-11-01 Macrolide Pharmaceuticals Inc. Macrolides with modified desosamine sugars and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780605A (en) * 1997-09-08 1998-07-14 Abbott Laboratories 6,9-bridged erythromycin derivatives
MXPA04011204A (es) * 2002-05-13 2005-06-08 Enata Pharmaceuticals Inc Derivados de cetoluros 6, 11-biciclicos.
US7064110B2 (en) * 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
WO2003095466A1 (en) * 2002-05-13 2003-11-20 Enanta Pharmaceuticals, Inc. 6,11 bicyclic erythromycin derivatives
US6878691B2 (en) * 2002-05-13 2005-04-12 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives

Also Published As

Publication number Publication date
WO2006119313A2 (en) 2006-11-09
AU2006242188A1 (en) 2006-11-09
CA2605295A1 (en) 2006-11-09
MX2007013730A (es) 2008-01-28
EP1885737A2 (en) 2008-02-13
JP2008540432A (ja) 2008-11-20
WO2006119313A3 (en) 2007-02-22
TW200716143A (en) 2007-05-01
EP1885737A4 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
US7265094B2 (en) 9N-substituted 6-11 bicyclic erythromycin derivatives
US7384922B2 (en) 6-11 bridged oxime erythromycin derivatives
US6764998B1 (en) 6,11-4C-bicyclic 9a-azalide derivatives
WO2005061525A1 (en) 6-11 bicyclic ketolide derivatives
EP1509538A1 (en) 6,11 bicyclic erythromycin derivatives
US20060252710A1 (en) 6-11 Bridged oxime erythromycin derivatives
MXPA04011204A (es) Derivados de cetoluros 6, 11-biciclicos.
US7291602B2 (en) 11,12-lactone bicyclolides
WO2009075923A2 (en) 6, 11-bridged biaryl macrolides
WO2003095466A1 (en) 6,11 bicyclic erythromycin derivatives
US7271155B2 (en) 9A, 11-2C-bicyclic 9a-azalide derivatives
US7414030B2 (en) 6-11 Bicyclic erythromycin derivatives
WO2007044927A2 (en) 6, 11-bridged tricyclic macrolides
WO2006065743A2 (en) Tetracylic bicyclolides
BRPI0610477A2 (pt) composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma infecção bacteriana, de uma inflamação e de fibrose cìstica em um paciente com necessidade do mesmo
WO2008014221A2 (en) Bridged carbamate macrolides
US6953782B2 (en) 11-C-substituted erythromycin derivatives
US7517859B2 (en) Spirocyclic bicyclolides
US20070259822A1 (en) 8a,11-bicyclic 8a-azalide derivatives
WO2008019240A2 (en) 3, 6-bridged tylosin derivatives
WO2008061189A1 (en) C-9 alkenylidine bridged macrolides
WO2004108746A2 (en) 11-12 bicyclic erythromycin derivatives
US6790835B1 (en) Bicyclic macrolide derivatives
WO2004108745A2 (en) 11-12 bicyclic erythromycin derivatives
WO2007115278A2 (en) 3,6,11-tricyclolide

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.